Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials

• LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies.
• Clinical benefit observed in 48% of evaluable cancer patients at or above the therapeutic dose threshold.
• Durable clinical benefits were observed in hard-to-treat tumors like glioblastoma multiforme (GBM), gastrointestinal stromal tumor (GIST) and thymic carcinoma.
• Biomarker insights highlight potential in DDR-mutated cancers, with marked tumor reductions in patients with CHK2, ATM, and STK11/KEAP1 alterations.
• Recommended Phase 2 dose (RP2D) established for targeted Phase 1b/2 trials in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and bladder cancer.
• The cancer indications in these targeted trials represent markets exceeding $6 billion in annual potential.
• The observations for LP-184 in the Phase 1a trial include clinical benefit for multiple patients who had reached the limits of or failed current available therapies.

Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced the successful completion of its Phase 1a clinical trial (NCT05933265) for LP-184. The trial met all primary endpoints, demonstrating a favorable safety and pharmacokinetic (PK) profile, and early signs of antitumor activity. Enrollment is complete, with several patients continuing treatment due to ongoing clinical benefit.

The open-label, multicenter, non-randomized study evaluated LP-184 in 63 patients with advanced relapsed or refractory solid tumors, including GBM. Primary objectives focused on safety, tolerability, PK, and determining a recommended Phase 2 dose (RP2D) when administered on Days 1 and 8 of a 21-day cycle.